It's not much of a contest right now.

Eli Lilly has asked the U.S. Supreme Court to overturn a part of a Civil War-era law that allows private whistleblowers to ...

Eli Lilly (NYSE:LLY) presented new four year data on EBGLYSS for moderate to severe atopic dermatitis at the AAD Annual Meeting. The open label extension study reports sustained skin clearance and ...

If you are interested in buying Eli Lilly (NYSE: LLY) today, it is most likely because of the success of the company's GLP-1 ...

Eli Lilly's stock has been receiving many upgrades after posting strong quarterly results in February.

After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.

Janus Henderson Investors, an investment management company, released its “Forty Fund” fourth-quarter 2025 investor letter. A ...

We just covered the Jim Cramer Stock Portfolio: Top 10 Stock Picks. Eli Lilly and Company (NYSE:LLY) ranks #9 (see the Jim ...

Eli Lilly, the maker of Zepbound and Mounjaro, said its experimental GLP-1 pill successfully helped adults with obesity lose weight in a Phase 3 trial, as the company moves closer to submitting the ...

You might be surprised to hear this, but off-the-shelf CAR-T therapies for cancer are still a thing. We preview an ...